A horseIt accelerated again this spring, with federal data showing that the rate of COVID infection in April was worse than the rate of non-death in Americans, and hospitalization remained the lowest among Americans with an increase.
It does not mean new informationare increasing the risk in some way. Ongoing research continues to provide strong evidence of the additional protection provided by amplified ammunition against infection, serious illness and death.
Instead, it emphasizes progress increasing complexity Measuring the effectiveness of the vaccine at this stage of the pandemic. This came as officials weighed whether to continue using key decisions to monitor intensified shootings and pandemics, including “raw performance indicators.”
It also serves to illustrate the complex truth facing health authorities during the recent wave of COVID-19: even as many Americans become more vulnerable to infection and spread of the virus, officials are wary of re-applying pandemic measures such as mask requirements.
“During this Omicron wave, we are seeing an increase in mild infections – a type of infection at home, discomfort, colds, being out of work, not good, but not the end of the world. It’s Omicron. Options are protected by antibodies and can cause these mild infections.” John Moore, a professor of microbiology and immunology at Will Cornell Medical College, told CBS News.
“So one of the dynamics here is that when people are vaccinated and empowered, they feel more protected than they actually are, so they increase the risk,” he said. “I think that’s the main engine of these statistics.”
On the CDC’s monthly updated board, the agency acknowledges several “factors that could affect the level of raw diseases through vaccination and booster dose status,” making it difficult to interpret recent trends.
The CDC released the leaflet a few months ago, as part of a call for better oversight of federal progress. It now includes data from vaccination records and positive COVID-19 tests from 30 health departments across the country.
Announced the rate for the week of April 23rdAmong the aggravated Americans, there were 119 cases per 100,000 people. This is a fraction of the levels in unvaccinated Americans who have more than doubled the number of infections in vaccinated but not vaccinated.
According to the CDC, this could be a “greater prevalence of previous infection” among those who have not been vaccinated and those who have not. More and more Americans may now abandon “preventive behaviors” such as wearing masks, leading to this uprising.
Some growing Americans may be more confident in looking for a lab test for COVID-19.not reported to health authorities.
“Home testing has become, in my opinion, the biggest concern in developed countries that will hinder our measurements,” CDC Ruth Link-Gelles said at a conference hosted by the National Foundation for Infectious Diseases last month.
Some federal officials have suggested the possibility of adopting a survey as an alternative way to monitor “basic facts” in cases of COVID-19, which the UK authorities have relied on, but are planning to upgrade such a system. does not appear close.
“Beyond this crisis, I think the future is a random choice. And this is an area we’re looking at carefully,” said Caitlin Rivers, a senior fellow at the agency’s disease forecasting team, at an event hosted by National Academies. Last week.
At the same time, federal officials are preparing to make key decisions on future COVID-19 vaccine shootings, which will increase the likelihood that additional bullets will be able to eradicate the latest version of the infection.
In a short time, CDC Director Dr. Rochelle Valenski recently told reporters that her agency is in talks with the Food and Drug Administration to extend the option.to more adults.
Currently, Americans over the age of 50 and some immunocompromised Americans are eligible for a fourth dose.
The next generation of vaccines and vaccinations
Further down the road, a panel of external vaccines advisers from the Food and Drug Administration is due to meet later this month to weigh data from new booster candidates released by Pfizer and BioNTech and Moderna.
BioNTech executives told investors last month that regulators had asked them to look at two-axis data specifically adapted for the Omicron variant, in addition to “bivalent vaccines” aimed at a mixture of mutations.
The release of these new vaccines will take about three months, said a senior White House official on COVID-19, Dr. Ashish Ja told reporters.
“There’s a bit of a problem here, because we don’t know how far the virus will develop over the next few months, but we have no choice but to make it available if we want to release hundreds of millions of doses. We need to start, ”he said. Peter Marx, the FDA’s top vaccine officer, said at a recent webinar hosted by the American Medical Association.
According to Mark, dual-frame shots may be approved, given the “moving room” that Omicron will offer for unexpected options.
Vaccines that offer even better “mucous immunity” – fighting the virus that infects the respiratory system for the first time – are still out of the question, Mark said.
“I think we are in a period of transition, and I want to make it clear once again that 2022-2023 is a year in which we should plan to try to minimize the impact of COVID-19 with the weapons we have,” Marx said at one point. The last story with the National Fund for Infectious Diseases.
“I am confident that by 2023-2024 we will begin to see second-generation SARS-CoV-2 vaccines,” he added.